CFT1946 + cetuximab

CFT1946 + cetuximab is an investigational combination therapy comprising CFT1946, an orally bioavailable, selective small molecule degrader of mutant BRAF V600 proteins, and cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). CFT1946 is a Proteolysis-Targeting Chimera (PROTAC) that selectively degrades mutant BRAF proteins via the ubiquitin-proteasome pathway, leading to inhibition of MAPK pathway signaling. Cetuximab binds EGFR and blocks ligand-induced activation, inhibiting EGFR-dependent cell proliferation. The combination is being developed for the treatment of BRAF V600 mutant solid tumors, particularly those resistant to BRAF inhibitors, with the aim to overcome resistance mechanisms and achieve more durable anti-tumor responses. CFT1946 was developed by C4 Therapeutics; cetuximab was originally developed by ImClone Systems and is currently marketed by Eli Lilly and Merck KGaA.

Other names

CFT-1946CFT1946CFT 1946